{"id":"febuxostat-ir","safety":{"commonSideEffects":[{"rate":null,"effect":"Liver function test abnormalities"},{"rate":null,"effect":"Gout flare (during initiation)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Febuxostat selectively inhibits xanthine oxidase, the key enzyme in the final steps of purine metabolism. By blocking this enzyme, it decreases serum and urinary uric acid levels, preventing urate crystal formation and deposition in joints and tissues. This mechanism is used to manage hyperuricemia and prevent gout attacks.","oneSentence":"Febuxostat is a selective xanthine oxidase inhibitor that reduces uric acid production by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:23.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic management of hyperuricemia in patients with gout"},{"name":"Prevention of gout flares"}]},"trialDetails":[{"nctId":"NCT02139046","phase":"PHASE3","title":"Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-04","conditions":"Gout","enrollment":1790},{"nctId":"NCT02128490","phase":"PHASE2","title":"Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05","conditions":"Gout, Moderate Renal Impairment","enrollment":189}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Uloric"],"phase":"phase_3","status":"active","brandName":"Febuxostat IR","genericName":"Febuxostat IR","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Febuxostat IR is a small molecule inhibitor of xanthine dehydrogenase/oxidase, a target enzyme involved in the production of uric acid. It is used to treat gout, a condition characterized by elevated levels of uric acid in the body, and has been studied in individuals with moderate renal impairment.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-02-13T00:00:00.000Z","mah":"TAKEDA PHARMS USA","brand_name_local":"ULORIC","application_number":"NDA021856"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}